Evofem Biosciences, Inc. · OTC:EVFM
Evofem Biosciences — IPO Roadshow (May 2018)
32 slides from Evofem Biosciences's IPO roadshow presentation, May 9, 2018
Slide 1: Amphora Market Research
Amphora Market Research Filed pursuant to Rule 433 Registration Statement No. 333-224190 May 9, 2018
Slide 2: Offering and forward-looking statements notice
The following presentation was made available in connection with an offering of securities by Evofem Biosciences, Inc. (the “Company” or “Evofem”) but was not prepared in contemplation of the offering. The presentation should be viewed only in connection with the Company’s registration statement on
Slide 3: Executive Summary
Executive Summary Key findings from the physician and patient research
Slide 4: Market Research Findings Overview
Market Research Findings Overview Market research from ~400 HCPs, 1400+ consumers, and 45 payers suggest Amphora® benefits will be of high interest for many women Project Research Type Timing Audience / Sample Primary Objective Initial Demand, Forecast, and Segmentation Quantitative and Qualitative
Slide 5: Amphora Key Findings
Amphora® Key Findings HCP/Payer Respondents were pleased to see a new non-hormonal option as they readily recognize the challenges with hormone based alternatives The addition of the base STI indication to the Amphora® contraception profile led to a significant increase in the frequency of physician
Slide 6: Target Segment Overview
Target Segment Overview HCP Consumer Target HCPs indicated they believe Amphora® would be appropriate for more than 15% of the women with whom they discuss contraception 71% of all respondents felt Amphora was for women like them “Supplementers” (28% of respondents) are highly engaged in their own h
Slide 7: Patients Respondent Overview
Patients Respondent Overview Key background information on consumer participants
Slide 8: Overview of Women at Risk for Pregnancy / STI
Overview of Women at Risk for Pregnancy / STI Source: S2, S97 S9, S11, S12, S13; n = 234 Short Term Rx LARC Non Rx None Overall N 86 57 57 34 2341 Average Age 33.9 33.7 38.1 38.9 35.6 % Age 18-35 59% 61% 33% 35% 50% Contraceptive Methods Used OC User 88% 9% 0% 0% 35% Hormonal IUD 0% 61% 0% 0% 15% No
Slide 9: Patients Contraception History
Patients Contraception History Patients’ current and prior use of contraceptives as well as key drivers of preference in the category
Slide 10: Different user groups value different contraceptive benefits
The different groups of users place very different values on the benefits of their current contraceptive Source: B10; n = 207 Reasons for Using Current Contraceptive (selected up to 3 responses) B10. Why did you decide to use your current approach to preventing pregnancy? Convenience and efficacy ar
Slide 11: Patients forego prescription contraception primarily to avoid hormones
Patients tend to forego prescription contraception primarily to avoid hormones Source: B14; n = 79 Main Reasons for Not Using a Prescription Contraceptive (selected up to 3 responses) B14. What are the main reasons you do not currently use a prescription form of birth control?
Slide 12: LARC users happier with choice; non/OTC users believe hormones have side effects
LARC users tend to be happier with their choice and more focused on efficacy, non/OTC users tend to believe hormones have significant side effects Source: B16; n = 207 Attitudes Related to Contraception (5 point scale, 1 = “Strongly Disagree”, 5 = “Strongly Agree”) B16. Please rate your level of agr
Slide 13: Patients STI Experiences and Treatment History
Patients STI Experiences and Treatment History Patients’ experiences with STIs, concerns and attitudes related to STIs, and current preferences and perceptions of available options
Slide 14: Patients use various methods to reduce STI risk
Patients use a variety of methods to reduce the risk of STIs, with the most common being monogamy Source: C8; n = 206 C8. Which of the following things do you do specifically to reduce the risk of getting an STI? Actions Taken to Reduce STI Risk
Slide 15: Most women show low concern for STIs
Most women show low levels of concern for STIs, believing they are in a monogamous relationship and their partner is disease free Source: C7; n = 206 Concern with Contracting an STI C7. How concerned are you about getting an STI? Average 3.8 4.3 3.7 4.5
Slide 16: Patient Responses to Contraceptive and STI Product Profiles
Patients Patient Responses to Contraceptive and STI Product Profiles Key treatment and demographic information by contraceptive method used
Slide 17: Interest in Amphora similar across groups
Interest in Amphora was similar across the different groups, while LARC users are the least likely to take action Source: B19; n = 207 Likelihood to Take Action: Contraception Profile (Product A) B19. If you heard about Product A, how likely would you be to take each of the following actions? a. Ask
Slide 18: Current Rx users showed greater interest in STI indication
Current prescription users showed greater interest in the STI indication, with other groups looking for a broader indication Source: C13, C15, C16; n = 207 Likelihood to Ask About Amphora by STI Profile (Products T1/T2/T3) T1 Reduction in chlamydia & gonorrhea T2 Reduction in chlamydia & gonorrhea;
Slide 19: Most patients who would ask would also request a prescription
Most patients who would ask their physician about Amphora would also request a prescription for the product Source: C13, C15, C16; n = 207 Likelihood to Request Amphora by STI Profile (Products T1/T2/T3) T1 Reduction in chlamydia & gonorrhea T2 Reduction in chlamydia & gonorrhea; some evidence in ot
Slide 20: STI benefits boost likelihood to accept doctor recommendation
STI benefits provide a greater boost to respondents’ likelihood to accept an Amphora recommendation from their doctor Source: D3, D8; n = 206 Likelihood to Select Amphora if HCP Recommends it by Contraception + STI Profile (Products AT1/AT2) A Contraception Only AT1 Contraception + reduction in chla
Slide 21: Physicians Current Market Landscape: Contraception
Physicians Current Market Landscape: Contraception
Slide 22: Monthly patient and contraception prescription volumes
In a typical month, respondents saw ~266 reproductive aged patients and wrote over 125 Rxs for contraception Source: S11, A5, E1; n = 100 Average Monthly Patient and Select Rx Volumes S11. In a typical month, how many prescriptions (both new and refills) do you write to treat / address each of the f
Slide 23: ~1/3 of women averse or contraindicated to hormonal options
~1/3 of women discussing contraception with their HCP are averse or contraindicated to hormonal options Source: B1, B2_2; n = 100 Fertility Status (Women 18 to 49) Eligibility and Receptivity to Hormonal Contraception B1. What portion of your patients of reproductive age (18-49 years old) is: B2. Pl
Slide 24: HCP opinions reinforce patients' aversion to hormones
HCP opinions reinforce the reality of patients’ aversion to hormones; a concern which is more common than concerns over vaginally delivered products Source: B10; n = 100 HCP Attitudes: Contraception Overall (5 point scale, 1 = “Strongly Disagree”, 5 = “Strongly Agree”) B10. Please indicate your leve
Slide 25: Key dynamics suggest unmet need still exists
Ultimately, several key dynamics related to contraceptive selection and usage suggest unmet need still exists in the market 78% of women 18 to 49 eligible for contraception 22% of these women are not receptive to hormones 8% are formally contraindicated 55% of women on Rx contraception using OCs HCP
Slide 26: Physicians Amphora Demand: Contraception-Only
Physicians Amphora Demand: Contraception-Only
Slide 27: HCP Rating: Compellingness of Amphora Contraception Profile
HCP Rating: Compellingness of Amphora Contraception Profile Note: Fixed / Base profile Source: B11; n = 100 Compellingness of Amphora Contraception Profile (10 point scale, 1 = “Not at all”, 10 = “Extremely”) B11. Based on the information provided, how compelling is Product A?
Slide 28: MDs most compelled by non-hormonal MOA, PRN use, lubrication
MDs were most compelled by Amphora’s non-hormonal MOA, PRN use, and lubrication qualities; education regarding efficacy of on-demand methods required for many HCP’s Note: Fixed / Base profile Source: B11_2, B11_3; n = 100 Most and Least Appealing Aspects of Amphora % Selecting Most Appealing % Selec
Slide 29: Physicians Amphora Demand: Contraception + STI
Physicians Amphora Demand: Contraception + STI
Slide 30: Contraception + STI version more compelling than either alone
MDs viewed a contraception + STI version of Amphora was more compelling than either indication on its own Note: Base profiles for each indication Source: B11, C9, D1; n = 100 Compellingness of Amphora Profiles (10 point scale, 1 = “Not at all”, 10 = “Extremely”) B11. Based on the information provide
Slide 31: Addition of STI indication more than doubled recommendations
MDs expected the addition of the base STI indication would more than doubled their recommendations for Amphora Note: Unadjusted; Assumes a box of 10 with $0 copay Source: B13, D2, D2_1; n = 100 Amphora Usage: Next 100 Patients HCPs would honor 85% of Amphora requests (vs. 82% for contraception-only)
Slide 32: Upside profile increased MD recommendation rate by ~20%
The upside contraception + STI profile increased the rate of MD Amphora recommendation by ~20% over the base (+6% absolute change) Note: Unadjusted; Assumes a box of 10 with $0 copay Source: B13, D2, D4; n = 100 Amphora Usage: Next 100 Patients B13. Please consider the next 100 reproductive-age pati